MCM
ZVRA icon

MAI Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

MAI Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-326
Closed -$3.04K – 4794
2026
Q1 		$3.04K Buy
326
+314
+2,617% +$2.83K ﹤0.01% 3753
2025
Q4 		$108 Hold
12
– – ﹤0.01% 4155
2025
Q3 		$115 Hold
12
– – ﹤0.01% 3736
2025
Q2 		$106 Hold
12
– – ﹤0.01% 3895
2025
Q1 		$90 Hold
12
– – ﹤0.01% 3362
2024
Q4 		$101 Buy
+12
New +$102 ﹤0.01% 3424

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MAI Capital Management's ZVRA Position: Q2 2026 in Review

MAI Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 326 shares — an estimated $3.04K sold.

MAI Capital Management first reported a position in ZVRA in Q4 2024 and held it in 6 quarters. The position peaked at $3.04K in Q1 2026. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • MAI Capital Management reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 326 Zevra Therapeutics shares in Q2 2026, an estimated $3.04K.
  • MAI Capital Management first reported a position in Zevra Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Zevra Therapeutics position peaked at $3.04K in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.